Molecular characterization of immortalized normal and dysplastic oral cell lines

Journal of Oral Pathology and Medicine

Volumn 44, Issue 5, 2015, Pages 329-336

  Dickman, Christopher T D ^a   Towle, Rebecca ^a   Saini, Rajan ^a   Garnis, Cathie ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cell lines; Copy number; Immortalized; MiRNA; Oral squamous cell carcinoma

Indexed keywords

GENOMIC DNA; MESSENGER RNA; MICRORNA;

ARTICLE; CANCER CELL LINE; CELL CYCLE REGULATION; CELL LINE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DYSPLASIA; GENE DOSAGE; GENE EXPRESSION PROFILING; GENOME; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; MOUTH; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; CYTOLOGY; DNA SEQUENCE; GENETICS; HEAD AND NECK TUMOR; HYPERPLASIA; MALE; MOUTH MUCOSA; MOUTH TUMOR; PATHOLOGY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HUMANS; HYPERPLASIA; MALE; MICRORNAS; MOUTH MUCOSA; MOUTH NEOPLASMS; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA;

EID: 84928238604     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12236     Document Type: Article

References (61)

1. Feng Z, Jiang B, Chandra J, et al. Human beta-defensins: differential activity against candidal species and regulation by Candida albicans. J Dent Res 2005; 84: 445-50.
2. Smith IM, Glazer CA, Mithani SK, et al. Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS ONE 2009; 4: e4961.
3. Alawi F, Lin P, Ziober B, et al. Dyskerin expression correlates with active proliferation independently of telomerase. Head Neck 2011; 33: 1041.
4. Jabr-Milane LS, van Vlerken LE, Yadav S, et al. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008; 34: 592-602.
5. Ha PK, Benoit NE, Yochem R, et al. A transcriptional progression model for head and neck cancer. Clin Cancer Res 2003; 9: 3058-64.
6. Tsui IF, Garnis C. Integrative molecular characterization of head and neck cancer cell model genomes. Head Neck 2010; 32: 1143-60.
7. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
8. Kozaki K-I, Imoto I, Mogi S, et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094-105.
9. Järvinen AK, Autio R, Kilpinen S, et al. High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. Genes Chromosom Cancer 2008; 47: 500-9.
10. Lin SC, Liu CJ, Chiu CP, et al. Establishment of OC3 oral carcinoma cell line and identification of NF-κB activation responses to areca nut extract. J Oral Pathol Med 2004; 33: 79-86.
11. McGregor F, Muntoni A, Fleming J, et al. Molecular changes associated with oral dysplasia progression and acquisition of immortality potential for its reversal by 5-azacytidine. Cancer Res 2002; 62: 4757-66.
12. Hunter KD, Thurlow JK, Fleming J, et al. Divergent routes to oral cancer. Cancer Res 2006; 66: 7405-13.
13. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996; 56: 2488-92.
14. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585-621.
15. Sato M, Vaughan MB, Girard L, et al. Multiple oncogenic changes (K-RASV12, p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006; 66: 2116-28.
16. Westerman KA, Leboulch P. Reversible immortalization of mammalian cells mediated by retroviral transfer and site-specific recombination. Proc Natl Acad Sci U S A 1996; 93: 8971-6.
17. Halbert C, Demers G, Galloway D. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 1991; 65: 473-8.
18. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-52.
19. Kim J, Ji M, DiDonato JA, et al. An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor. In Vitro Cell Dev Biol Anim 2011; 47: 2-9.
20. Tsao S-W, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995; 218: 499-507.
21. Rheinwald JG, Hahn WC, Ramsey MR, et al. A two-stage, p16INK4A-and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol 2002; 22: 5157-72.
22. Dickson MA, Hahn WC, Ino Y, et al. Human keratinocytes that express hTERT and also bypass a p16INK4a-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 2000; 20: 1436-47.
23. Burns J, Clark L, Yeudall W, et al. The p53 status of cultured human premalignant oral keratinocytes. Br J Cancer 1994; 70: 591-5.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
25. Towle R, Truong D, Hogg K, et al. Global analysis of DNA methylation changes during progression of oral cancer. Oral Oncol 2013; 49: 1033-42.
26. Ishkanian AS, Malloff CA, Watson SK, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet 2004; 36: 299-303.
27. Wong KK, DeLeeuw RJ, Dosanjh NS, et al. A comprehensive analysis of common copy-number variations in the human genome. Am J Med Genet 2007; 80: 91-104.
28. Lockwood W, Chari R, Coe B, et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene 2008; 27: 4615-24.
29. Tsui IFL, Rosin MP, Zhang L, et al. Multiple aberrations of chromosome 3p detected in oral premalignant lesions. Cancer Prev Res (Phila) 2008; 1: 424-9.
30. Khojasteh M, Lam WL, Ward RK, et al. A stepwise framework for the normalization of array CGH data. BMC Bioinformatics 2005; 6: 274.
31. Chi B, deLeeuw RJ, Coe BP, et al. MD-SeeGH: a platform for integrative analysis of multi-dimensional genomic data. BMC Bioinformatics 2008; 9: 243.
32. Carro A, Rico D, Rueda OM, et al. waviCGH: a web application for the analysis and visualization of genomic copy number alterations. Nucleic Acids Res 2010; 38: W182-7.
33. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
34. Smoot ME, Ono K, Ruscheinski J, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011; 27: 431-2.
35. Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009; 25: 1091-3.
36. Towle R, Gorenchtein M, Dickman C, et al. Dysregulation of microRNAs across oral squamous cell carcinoma fields in non-smokers. JBR J Interdiscip Med Dent Sci 2014; 131: 1-9.
37. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 2009; 10: R64.
38. Chang DD, Park N-H, Denny CT, et al. Characterization of transformation related genes in oral cancer cells. Oncogene 1998; 16: 1921-30.
39. Hawley-Nelson P, Vousden KH, Hubbert NL, et al. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8: 3905-10.
40. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
41. Pickering CR, Zhang J, Yoo S-Y, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 2013; 3: 770-81.
42. Gjoerup OV, Wu J, Chandler-Militello D, et al. Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci U S A 2007; 104: 8334-9.
43. Chang T-C, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-52.
44. Scapoli L, Palmieri A, Lo ML, et al. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010; 23: 1229-34.
45. Kumar M, Lu Z, Takwi AAL, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2010; 30: 843-53.
46. Shay J, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-91.
47. Tabori U, Nanda S, Druker H, et al. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 2007; 67: 1415-8.
48. Edington KG, Loughran OP, Berry IJ, et al. Cellular immortality: a late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss. Mol Carcinog 1995; 13: 254-65.
49. Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2002; 99: 12606-11.
50. Chapman EJ, Kelly G, Knowles MA. Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol Cancer Res 2008; 6: 1154-68.
51. Fuchs E, Green H. Regulation of terminal differentiation of cultured human keratinocytes by vitamin A. Cell 1981; 25: 617-25.
52. Kopan R, Traska G, Fuchs E. Retinoids as important regulators of terminal differentiation: examining keratin expression in individual epidermal cells at various stages of keratinization. J Cell Biol 1987; 105: 427-40.
53. Sdek P, Zhang Z, Cao J, et al. Alteration of cell-cycle regulatory proteins in human oral epithelial cells immortalized by HPV16 E6 and E7. Int J Oral Maxillofac Surg 2006; 35: 653-7.
54. Boldrup L, Coates PJ, Laurell G, et al. Differences in p63 expression in SCCHN tumours of different sub-sites within the oral cavity. Oral Oncol 2011; 47: 861-5.
55. Krump M, Ehrmann J. Differences in CD44s expression in HNSCC tumours of different areas within the oral cavity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157: 280-3.
56. Severino P, Alvares AM, Michaluart P, et al. Global gene expression profiling of oral cavity cancers suggests molecular heterogeneity within anatomic subsites. BMC Res Notes 2008; 1: 113.
57. Boldrup L, Coates PJ, Wahlgren M, et al. Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins. J Carcinog 2012; 11: 18.
58. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-16.
59. Abouzeid WM, Mokhtar SA, Mahdy NH, et al. Time trends, and survival of patients with oral and pharyngeal malignancies. J Dev Biol Tissue Eng 2011; 3: 33-41.
60. Silverman S. Demographics and occurrence of oral and pharyngeal cancers The outcomes, the trends, the challenge. J Am Dent Assoc 2001; 132: 7S-11S.
61. Munro J, Stott FJ, Vousden KH, et al. Role of the alternative INK4A proteins in human keratinocyte senescence: evidence for the specific inactivation of p16INK4A upon immortalization. Cancer Res 1999; 59: 2516-21.